Patents by Inventor Steve Orndorff

Steve Orndorff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11052060
    Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of autoimmune diseases or Celiac disease by modulating the binding of DQ8 MHC class II molecules to antigenic peptides or fragments of antigenic peptides.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: July 6, 2021
    Assignees: The Regents of the University of Colorado, a body corporate, ImmunoMolecular Therapeutics, Inc.
    Inventors: Steve Orndorff, Aaron Michels
  • Patent number: 11013707
    Abstract: Methods of administering methyldopa to a subject in a fasting state to increase bioavailability of the methyldopa.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: May 25, 2021
    Assignees: The Regents of the University of Colorado, a body corporate, ImmunoMolecular Therapeutics, Inc.
    Inventors: Steve Orndorff, Aaron Michels
  • Publication number: 20190290607
    Abstract: Methods of administering methyldopa to a subject in a fasting state to increase bioavailability of the methyldopa.
    Type: Application
    Filed: March 23, 2018
    Publication date: September 26, 2019
    Inventors: Steve Orndorff, Aaron Michels
  • Publication number: 20190262301
    Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of autoimmune diseases or Celiac disease by modulating the binding of DQ8 MHC class II molecules to antigenic peptides or fragments of antigenic peptides.
    Type: Application
    Filed: March 19, 2019
    Publication date: August 29, 2019
    Inventors: Steve Orndorff, Aaron Michels
  • Patent number: 9820957
    Abstract: Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of D-?-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of D-?-methyldopa.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: November 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Steve Orndorff, Aaron Michels, Peter Gottlieb
  • Publication number: 20170273927
    Abstract: Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of D-?-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of D-?-methyldopa.
    Type: Application
    Filed: March 22, 2017
    Publication date: September 28, 2017
    Inventors: Steve Orndorff, Aaron Michels, Peter Gottlieb
  • Publication number: 20060189545
    Abstract: Methods and composition for treating or preventing, the occurrence of senile dementia of the Alzheimer's type, or other conditions arising from reduced neuronal metabolism and leading to lessened cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compounds to said patient at a level to produce an improvement in cognitive ability.
    Type: Application
    Filed: March 8, 2004
    Publication date: August 24, 2006
    Inventors: Samuel Henderson, Steve Orndorff, Lawrence Melvin